NT-proBNP Best predictor of cardiovascular events and cardiovascular mortality in secondary prevention in very old age: The Leiden 85-plus study

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Van Peet, Petra G ^a   Drewes, Yvonne M ^a   De Craen, Anton J M ^a   Gussekloo, Jacobijn ^a   De Ruijter, Wouter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE; BLOOD; CARDIOVASCULAR DISEASES; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MORBIDITY; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

AGE FACTORS; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MORBIDITY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE;

EID: 84894252359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081400     Document Type: Article

References (49)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD et al. (2011) Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 123: e18-e209. doi:10.1161/CIR.0b013e3182009701. PubMed: 21160056. CIR. 0b013e3182009701 . PII;Available: . doi:10.1161/CIR. 0b013e3182009701
2. McDermott MM (2007) The international pandemic of chronic cardiovascular disease. JAMA 297: 1253-1255. doi:10.1001/jama.297.11.1253. PubMed: 17374819.
3. Kerr AJ, Broad J, Wells S, Riddell T, Jackson R (2009) Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart 95: 125-129. doi:10.1136/hrt. 2007.140905. PubMed: 18381374. hrt.2007.140905 . PII;Available: . doi:10.1136/hrt.2007.140905
4. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr., Ohman EM et al. (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297: 1197-1206. doi:10.1001/jama. 297.11.1197. PubMed: 17374814. 297/11/1197 . PII;Available: . doi: 10.1001/jama.297.11.1197
5. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP et al. (2009) Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J 30: 1195-1202. doi:10.1093/eurheartj/ehp099. PubMed: 19339264. ehp099 . PII;Available: . doi:10.1093/eurheartj/ehp099
6. Arima H, Tzourio C, Butcher K, Anderson C, Bousser MG, et al. (2006) Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke 37: 1497-1502. 01.STR0000221212.36860.c9 [pii];Available online at: 10.1161/01.STR.0000221212.36860.c9 [doi]
7. Touze E, Varenne O, Chatellier G, Peyrard S, Rothwell PM, et al. (2005) Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke 36: 2748-2755. 01.STR0000190118.02275.33 [pii];Available online at: 10.1161/01.STR.0000190118.02275.33 [doi]
8. Alhusban A, Fagan SC (2011) Secondary prevention of stroke in the elderly: a review of the evidence. Am J Geriatr Pharmacother 9: 143-152. S1543-5946(11)00050-X [pii];Available online at: 10.1016/j.amjopharm.2011.04.002 [doi]
9. Asberg S, Henriksson KM, Farahmand B, Asplund K, Norrving B et al. (2010) Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register. Stroke 41: 1338-1342. doi:10.1161/STROKEAHA.110.580209. PubMed: 20522818. STROKEAHA.110.580209 . PII;Available: . doi:10.1161/STROKEAHA.110.580209
10. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, et al. (2007) Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115: 700-707. CIRCULATIONAHA106.654756 [pii];Available online at: 10.1161/CIRCULATIONAHA.106. 654756 [doi]
11. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630. doi: 10.1016/S0140-6736(02) 11600-X. PubMed: 12457784. S014067360211600X . PII.
12. Macchia A, Romero M, D'Ettorre A, Mariani J, Tognoni G (2012) Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: an analysis of three successive cohorts between 2003 and 2008. Eur Heart J 33: 515-522. doi:10.1093/eurheartj/ehr410. PubMed: 22096090. ehr410 . PII;Available: . doi:10.1093/eurheartj/ehr410
13. de Ruijter W, de Waal MW, Gussekloo J, Assendelft WJ, Blom JW (2010) Time trends in preventive drug treatment after myocardial infarction in older patients. Br J Gen Pract 60: 47-49: 47-9. doi: 10.3399/bjgp10X482103. PubMed: 20040168.
14. Zuckerman IH, Yin X, Rattinger GB, Gottlieb SS, Simoni-Wastila L et al. (2012) Effect of Exposure to Evidence-Based Pharmacotherapy on Outcomes After Acute Myocardial Infarction in Older Adults. J Am Geriatr Soc, 60: 1854-61. doi:10.1111/j.1532-5415.2012.04165.x. PubMed: 23003000.
15. Subherwal S, Patel MR, Kober L, Peterson ED, Jones WS, et al. (2012) Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation 126: 1345-1354. CIRCULATIONAHA112.108787 [pii];Available online at: 10.1161/CIRCULATIONAHA.112.108787 [doi]
16. Naderi SH, Bestwick JP, Wald DS (2012) Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients. Am J Med, 125: S0002-S9343. PubMed: 22748400. 12)00018-6 . PII;Available: . doi:10.1016/j.amjmed.2011.12.013
17. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y et al. (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295: 180-189. doi:10.1001/jama.295.2.180. PubMed: 16403930. 295/2/180 . PII;Available: . doi:10.1001/jama.295.2.180
18. Uthoff H, Staub D, Socrates T, Meyerhans A, Bundi B et al. (2010) PROCAM-, FRAMINGHAM-, S. VASA 39: 325-333. doi: 10.1024/0301-1526/a000057. PubMed: 21104622.
19. van Peet PG, Drewes YM, de Craen AJ, Westendorp RG, Gussekloo J et al. (2012) Prognostic value of cardiovascular disease status: the Leiden 85-plus study. Age (Dordr) . 10.1007/s11357-012-9443-5 [doi].
20. Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW et al. (2013) Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart 99: 866-872. doi: 10.1136/heartjnl-2013-303640. PubMed: 23574971. heartjnl-2013-303640 . PII;Available: . doi:10.1136/heartjnl-2013-303640
21. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G et al. (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302: 49-57. doi: 10.1001/jama.2009.943. PubMed: 19567439. 302/1/49 . PII;Available: . doi:10.1001/jama.2009.943
22. Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegenthart R et al. (2012) Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 156: 438-444. doi: 10.7326/0003-4819-156-6-201203200-00006. PubMed: 22431676. 156/6/438 . PII;Available: . doi: 10.1059/0003-4819-156-6-201203200-00006
23. Wannamethee SG, Welsh P, Lowe GD, Gudnason V, Di Angelantonio E, et al. (2011) N-terminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 58: 56-64. S0735-1097(11)01343-X [pii];Available online at: 10.1016/j.jacc.2011.02.041 [doi]
24. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, et al. (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121: 2388-2397. CIRCULATIONAHA109.901413 [pii];Available online at: 10.1161/CIRCULATIONAHA.109.901413 [doi]
25. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M (2008) Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 83: 1203-1212. S0025-6196(11)60637-X [pii];Available online at: 10.4065/83.11.1203 [doi]
26. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB et al. (2007) N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297: 169-176. doi:10.1001/jama.297.2.169. PubMed: 17213400. 297/2/169 . PII;Available: . doi: 10.1001/jama.297.2.169
27. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA (2008) Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med 121: 50-57. S0002-9343(07)00844-3 [pii];Available online at: 10.1016/j.amjmed.2007.06.030 [doi]
28. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, et al. (2006) Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 114: 201-208. CIRCULATIONAHA105.590927 [pii];Available online at: 10.1161/CIRCULATIONAHA.105.590927 [doi]
29. Battistoni A, Rubattu S, Volpe M (2012) Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol, 157: S0167-S5273. PubMed: 21763018. 11)00606-1 . PII;Available: . doi:10.1016/j.ijcard.2011.06.066
30. Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, et al. (2007) C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 115: 981-989. CIRCULATIONAHA106.643114 [pii];Available online at: 10.1161/CIRCULATIONAHA.106.643114 [doi]
31. Ford I, Bezlyak V, Stott DJ, Sattar N, Packard CJ et al. (2009) Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis. PLoS Med 6: e16. doi:10.1371/journal.pmed.1000016. PubMed: 19166266. 08-PLME-RA-1471 . PII;Available: . doi:10.1371/journal.pmed.1000016
32. van der Wiel AB, van Exel E, de Craen AJ, Gussekloo J, Lagaay AM et al. (2002) A high response is not essential to prevent selection bias: results from the Leiden 85-plus study. J Clin Epidemiol 55: 1119-1125. doi:10.1016/S0895- 4356(02)00505-X. PubMed: 12507676. S089543560200505X . PII.
33. Macfarlane PW, Latif S (1996) Automated serial ECG comparison based on the Minnesota code. J Electrocardiol 29 Suppl: 29-34. doi: 10.1016/S0022- 0736(96)80016-1. PubMed: 9238374.
34. Verduijn M, Grootendorst DC, Dekker FW, Jager KJ, le Cessie S (2011) The analysis of competing events like cause-specific mortality - beware of the Kaplan-Meier method. Nephrol Dial Transplant 26: 56-61. doi:10.1093/ndt/gfq661. PubMed: 21059831. gfq661 . PII;Available: . doi:10.1093/ndt/gfq661
35. Pencina MJ, d'Agostino RB, Vasan RS (2010) Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 48: 1703-1711. doi:10.1515/CCLM.2010.340. PubMed: 20716010.
36. Pencina MJ, D'Agostino RB Sr., Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30: 11-21. doi:10.1002/sim.4085. PubMed: 21204120.
37. Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172. doi:10.1002/sim.2929. PubMed: 17569110.
38. Pencina MJ, D'Agostino RB, Pencina KM, Janssens AC, Greenland P (2012) Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 176: 473-481. doi:10.1093/aje/kws207. PubMed: 22875755. kws207 . PII;Available: . doi:10.1093/aje/kws207
39. Van Houwelingen JC, le Cessie S (1990) Predictive value of statistical models. Stat Med 9: 1303-1325. doi:10.1002/sim.4780091109. PubMed: 2277880.
40. Zhang M, Lu S, Wu X, Chen Y, Song X, et al. (2012) Multimarker approach for the prediction of cardiovascular events in patients with mild to moderate coronary artery lesions. A 3-year follow-up study. Int Heart J 53: 85-90. DN/JST.JSTAGE/ihj/53.85 [pii].
41. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ et al. (2009) Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 338: a3083. doi: 10.1136/bmj.a3083. PubMed: 19131384.
42. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL et al. (2000) Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 102: 1227-1232. doi:10.1161/01.CIR.102.11. 1227. PubMed: 10982535.
43. Vaes B, de Ruijter W, Degryse J, Westendorp RG, Gussekloo J (2009) Clinical relevance of a raised plasma N-terminal pro-brain natriuretic peptide level in a population-based cohort of nonagenarians. J Am Geriatr Soc 57: 823-829. doi:10.1111/j.1532-5415.2009.02218.x. PubMed: 19470010. JGS2218 . PII;Available: . doi:10.1111/j.1532-5415.2009.02218.x
44. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, et al. (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 120: 2177-2187. CIRCULATIONAHA109.884866 [pii];Available online at: 10.1161/CIRCULATIONAHA.109. 884866 [doi]
45. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S et al. (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358: 2107-2116. doi: 10.1056/NEJMoa0707064. PubMed: 18480203. 358/20/2107 . PII;Available: . doi:10.1056/NEJMoa0707064
46. Pikula A, Beiser AS, Decarli C, Himali JJ, Debette S, et al. (2012) Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the framingham offspring study. Circulation 125: 2100-2107. CIRCULATIONAHA110. 989145 [pii];Available online at: 10.1161/CIRCULATIONAHA.110.989145 [doi]
47. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J et al. (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293: 1609-1616. doi:10.1001/jama.293.13.1609. PubMed: 15811980. 293/13/1609 . PII;Available: . doi:10.1001/jama.293.13.1609
48. Strandberg TE, Tilvis RS (2000) C-Reactive Protein, Cardiovascular Risk Factors, and Mortality in a Prospective Study in the Elderly. Arterioscler Thromb Vasc Biol 20: 1057-1060. doi:10.1161/01.ATV.20.4.1057. PubMed: 10764673.
49. Manzano-Fernandez S, Boronat-Garcia M, Albaladejo-Oton MD, Pastor P, Garrido IP, et al. (2009) Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol 103: 1753-1759. S0002-9149(09)00611-0 [pii];Available online at: 10.1016/j.amjcard.2009.02.029 [doi]